Talsaklidin (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Talsaklidin" in Serbian language version.

refsWebsite

Global rank Serbian rank

4^th place

8^th place

2^nd place

4^th place

6^th place

5^th place

archive.org

Ensinger HA; Doods HN; Immel-Sehr AR; et al. (1993). „WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties”. Life Sciences. 52 (5-6): 473—80. PMID 8441328. doi:10.1016/0024-3205(93)90304-L.
Walland A, Burkard S, Hammer R, Tröger W (1997). „In vivo consequences of M1-receptor activation by talsaclidine”. Life Sciences. 60 (13-14): 977—84. PMID 9121364. doi:10.1016/S0024-3205(97)00037-4.
Terry AV, Buccafusco JJ, Borsini F, Leusch A (2002). „Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine”. Psychopharmacology. 162 (3): 292—300. PMID 12122487. doi:10.1007/s00213-002-1105-3.
Adamus WS, Leonard JP, Tröger W (1995). „Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease”. Life Sciences. 56 (11-12): 883—90. PMID 10188789. doi:10.1016/0024-3205(95)00024-Z.

doi.org

Ensinger HA; Doods HN; Immel-Sehr AR; et al. (1993). „WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties”. Life Sciences. 52 (5-6): 473—80. PMID 8441328. doi:10.1016/0024-3205(93)90304-L.
Walland A, Burkard S, Hammer R, Tröger W (1997). „In vivo consequences of M1-receptor activation by talsaclidine”. Life Sciences. 60 (13-14): 977—84. PMID 9121364. doi:10.1016/S0024-3205(97)00037-4.
Wienrich M; Meier D; Ensinger HA; et al. (2001). „Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man”. Life Sciences. 68 (22-23): 2593—600. PMID 11392631. doi:10.1016/S0024-3205(01)01057-8.
Terry AV, Buccafusco JJ, Borsini F, Leusch A (2002). „Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine”. Psychopharmacology. 162 (3): 292—300. PMID 12122487. doi:10.1007/s00213-002-1105-3.
Adamus WS, Leonard JP, Tröger W (1995). „Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease”. Life Sciences. 56 (11-12): 883—90. PMID 10188789. doi:10.1016/0024-3205(95)00024-Z.

nih.gov

ncbi.nlm.nih.gov

Ensinger HA; Doods HN; Immel-Sehr AR; et al. (1993). „WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties”. Life Sciences. 52 (5-6): 473—80. PMID 8441328. doi:10.1016/0024-3205(93)90304-L.
Walland A, Burkard S, Hammer R, Tröger W (1997). „In vivo consequences of M1-receptor activation by talsaclidine”. Life Sciences. 60 (13-14): 977—84. PMID 9121364. doi:10.1016/S0024-3205(97)00037-4.
Wienrich M; Meier D; Ensinger HA; et al. (2001). „Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man”. Life Sciences. 68 (22-23): 2593—600. PMID 11392631. doi:10.1016/S0024-3205(01)01057-8.
Terry AV, Buccafusco JJ, Borsini F, Leusch A (2002). „Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine”. Psychopharmacology. 162 (3): 292—300. PMID 12122487. doi:10.1007/s00213-002-1105-3.
Adamus WS, Leonard JP, Tröger W (1995). „Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease”. Life Sciences. 56 (11-12): 883—90. PMID 10188789. doi:10.1016/0024-3205(95)00024-Z.